AbbVie Reports the CHMP’s Positive Opinion of Skyrizi (Risankizumab) to Treat Ulcerative Colitis

Shots: The CHMP grants a positive opinion to Skyrizi for treating moderate to severely active UC in adults with inadequate or lost response and were intolerant to conventional or biologic therapy. Final decision is anticipated in Q3’24 The positive opinion was based on the P-III (INSPIRE) study, assessing Skyrizi (induction treatment: 1200mg, IV, 0,4…

ByDipanshu DixitMay 31, 2024

CXO TALKS

Spotlight Interview: Moreno Perugini in a Candid Conversation with PharmaShots

Following the Reuters Events Pharma USA 2024, PharmaShots brings an engaging conversation with Moreno Perugini, President, of Néstle Health Science. Moreno begins the conversation by highlighting Néstle’s journey to become a full-fledged pharma company through a series of acquisitions and deals. Moreno recalls Néstle’s transitioning into a pharmaceutical company when the company got the rights for Zenpep,…

ByHimanshu SehgalApril 15, 2024

TOP 20

Top 20 Women Health Focusing Companies of 2024 Based on Market Cap

Shots: While the World celebrated International Women’s Day, PharmaShots was busy preparing an exciting report on the Top 20 Women Health Focusing Companies Based on Market Cap Women's Health Market size was valued at $38.10B in 2023 and is expected to register $58.10B by 2030 with a CAGR of 4.9 percent. AbbVie managed to secure…

ByPrince GiriMarch 14, 2024

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2023

Shots: The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1B The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…

BySenior EditorJanuary 16, 2024

VIEWPOINTS

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Shots: Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…

BySaurabh ChaubeyJanuary 10, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in August 2023

Shots: The EMA approved 5 New Chemical Entity (NCE) and 6 Biologic Drugs in August 2023, leading to treatments for patients and advances in the healthcare industry In August 2023, the major highlight drugs were Aquipta (atogepant) approved for the preventive treatment of migraine in adults & Opdivo (nivolumab) as an adjuvant treatment for completely…

BySenior EditorSeptember 28, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Shots: The EMA approved 9 New Chemical Entity (NCE) and 5 Biologic Drugs in July 2023, leading to treatments for patients and advances in the healthcare industry In July 2023, the major highlights drugs were Soliris approval for refractory generalised myasthenia gravis and Trodelvy for pre-treated HR+/HER2- metastatic breast cancer PharmaShots has compiled a list…

BySenior EditorAugust 24, 2023

VIEWPOINTS

Tahi Ahmadi and Asud Khaliq Share their Views on EPKINLY (epcoritamab) U.S. FDA Approval in DLBCL

Shots: Tahi and Asud initiated the conversation with an overview of EPKINLYTM (epcoritamab) and its approval by the U.S. FDA to treat R/R DLBCL They then spoke about the study design and results from the EPCORE NHL-1 P-I/II trial that served as the basis for the U.S. FDA approval of EPKINLY. EPKINLY is being co-developed and co-commercialized by Genmab and AbbVie. Both companies are evaluating…

BySenior EditorAugust 2, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in June 2023

Shots: The EMA approved 7 New Chemical Entity (NCE) and 4 Biologic Drugs in June 2023, leading to treatments for patients and advances in the healthcare industry In June 2023, the major highlights drugs were Jardiance approval for CKD patients, Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis PharmaShots has compiled a list of a…

BySenior EditorJuly 28, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2023

Shots: The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9B The second quarter of the year also showcases multiple approvals of the therapies…

BySenior EditorJuly 3, 2023

AbbVie Reports the CHMP’s Positive Opinion of Skyrizi (Risankizumab) to Treat Ulcerative Colitis

Spotlight Interview: Moreno Perugini in a Candid Conversation with PharmaShots

Top 20 Women Health Focusing Companies of 2024 Based on Market Cap

PharmaShots’ Key Highlights of Fourth Quarter 2023

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Insights+: EMA Marketing Authorization of New Drugs in August 2023

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Tahi Ahmadi and Asud Khaliq Share their Views on EPKINLY (epcoritamab) U.S. FDA Approval in DLBCL

Insights+: EMA Marketing Authorization of New Drugs in June 2023

PharmaShots’ Key Highlights of Second Quarter 2023

Contact US

OUR INFORMATION

FOLLOW US